Short answer
Selank research peptide is a synthetic heptapeptide analog of the endogenous immunomodulatory tetrapeptide tuftsin (sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro). It is studied in neuropeptide research for anxiolytic-like, neurotrophic, and immunomodulatory activity in laboratory models. It is sold as a lyophilized research powder and is not for human use.
What is the Selank research peptide?
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It is a designed analog of tuftsin, the endogenous tetrapeptide Thr-Lys-Pro-Arg, which corresponds to a fragment of the heavy chain of human immunoglobulin G. In Selank, the tuftsin core is extended at the C-terminus with a Pro-Gly-Pro tripeptide, a modification intended to increase metabolic stability relative to the native tetrapeptide.
As a research compound, Selank is of interest because it sits at the intersection of two research traditions: the immunomodulatory pharmacology of tuftsin and the neuropeptide research field concerned with small peptides that modulate central nervous system signaling. The peptide is generally supplied as a lyophilized powder and is reconstituted in the laboratory according to standard peptide handling protocols.
Tuftsin analog lineage and neuropeptide research
Tuftsin was first described in the early 1970s as a phagocytosis-stimulating peptide released from the Fc domain of immunoglobulin G. Its immunomodulatory properties made it a frequent subject of immunology research. The development of Selank as a tuftsin analog extended this line of work toward the central nervous system, where the peptide has been studied for anxiolytic-like and neurotrophic activity in rodent models.
This lineage is important for researchers because it explains the unusual combination of activities reported for Selank. The peptide is often described as both a tuftsin-related immunomodulator and a neuroactive heptapeptide, and published studies have examined effects on anxiety-related behavior, memory, and immune function. Within the broader nootropic research category, Selank is typically grouped with other small regulatory peptides studied for their effects on learning, memory, and stress-related behavior.
Mechanism of action: GABAergic, monoamine, and enkephalin systems
The anxiolytic-like activity of Selank reported in animal models has been attributed to several interacting mechanisms:
Research history of Selank
Selank was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in Moscow, where it emerged from a program of research on regulatory peptides related to tuftsin. Early work characterized the peptide's stability and its interactions with peptidases in blood, and subsequent studies explored behavioral effects in rodents.
The peptide has been studied across several decades, with research appearing in journals including the Bulletin of Experimental Biology and Medicine, Behavioural Neurology, and Protein & Peptide Letters. The research record includes animal behavioral studies, receptor binding assays, and ex vivo analyses of neurotrophin content in brain tissue.
Research findings: anxiolytic-like activity, BDNF, and memory
Published findings relevant to the anxiolytic-like and neurotrophic profile of Selank include the following:
These findings come from controlled laboratory studies in rodents and ex vivo tissue preparations. They describe effects observed in research models and do not represent established benefits in any human population.
Neurotrophic mechanisms and intranasal delivery
A recurring theme in the Selank literature is the relationship between the peptide's neurotrophic effects and its behavioral profile. Brain-derived neurotrophic factor (BDNF) is a key regulator of synaptic plasticity, and several studies have examined whether Selank's effects on memory and stress-related behavior are accompanied by changes in BDNF content in the hippocampus and frontal cortex. The ethanol-induced memory impairment study cited above reported exactly this pattern: protection against memory disturbance was paralleled by regulation of BDNF content in those regions [4]. An earlier in vivo study reported that intranasal Selank regulated BDNF expression in the rat hippocampus, linking the peptide to the same neurotrophin pathway studied extensively in cognitive and mood research [5].
Route of administration is also a practical consideration in this research. The Russian research program that developed Selank studied the peptide primarily by the intranasal route, which delivers the small peptide directly into the central nervous system through the olfactory and trigeminal pathways and bypasses first-pass hepatic metabolism. In laboratory research, however, the compound is commonly reconstituted from lyophilized powder and handled according to the investigator's own protocol, so the route used in any given study depends on the experimental design rather than on a fixed formulation.
The combination of anxiolytic-like, neurotrophic, and immunomodulatory activities is what makes Selank an interesting subject within neuropeptide research. Because the peptide was designed as a stabilized tuftsin analog, it also retains the immunomodulatory lineage of its parent molecule, which is studied for effects on phagocytosis and immune-cell function. Researchers should be careful, however, to treat these as distinct lines of evidence: the anxiolytic-like findings come mainly from rodent behavioral models, the BDNF findings from ex vivo and in vivo neurochemistry, and the immunomodulatory findings from the tuftsin pharmacology literature. They are complementary but not interchangeable lines of support.
Research limitations and interpretation
Several caveats should guide how the Selank literature is read. First, most of the published studies originate from Russian academic institutions, and independent Western replication remains limited; the evidence base is coherent but geographically concentrated. Second, the human studies that exist enrolled relatively small numbers of participants, which limits the strength of any clinical inference drawn from them. Third, much of the mechanistic work is in rodent behavioral models or ex vivo tissue preparations, and in vitro conditions do not reproduce the full complexity of an intact nervous system. These limitations do not reduce the value of the compound as a research tool, but they mean findings should be treated as evidence in an active research program rather than as settled conclusions. For the laboratory, the practical implication is straightforward: rely on the primary literature, reproduce conditions carefully, and treat the peptide as a well-characterized reagent whose biology is still being mapped.
Selank compared with related neuropeptide research compounds
Within neuropeptide research, Selank is frequently discussed alongside Semax, another synthetic heptapeptide developed in the same research program. Both peptides share the C-terminal Pro-Gly-Pro motif, but their sequences and reported mechanisms differ: Selank is a tuftsin analog studied for anxiolytic-like and immunomodulatory activity, while Semax is an ACTH(4-10) analog studied primarily in cognitive research models. Researchers interested in the comparison can read our Semax research peptide article. PEPMAKE also offers both peptides individually and as a Semax + Selank Blend for laboratories that wish to study the two compounds together.
How to evaluate quality when buying Selank for research
Research-grade Selank should come with verifiable quality data. Before ordering, confirm the following:
PEPMAKE provides batch documentation through the batch verification portal, and the Selank product page shows the documentation supplied with each order. PEPMAKE products are supplied for in-vitro laboratory research only.
Storage and handling of lyophilized Selank
Lyophilized Selank is most stable when stored cold and dry. Standard laboratory guidance includes storing the powder at or below -20 degrees C, protecting it from light and moisture, and minimizing repeated exposure to ambient temperature. After reconstitution with an appropriate laboratory-grade solvent, aliquoting the solution helps avoid repeated freeze-thaw cycles. Always follow the manufacturer's documentation and your laboratory's stability protocol, and keep the compound clearly labeled for research use only.
FAQ
What is Selank?
Selank is a synthetic heptapeptide (sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro) that is an analog of the endogenous tetrapeptide tuftsin. It is sold for laboratory research only.
How does Selank differ from Semax?
Both are synthetic heptapeptides sharing a Pro-Gly-Pro motif, but Selank is a tuftsin analog studied for anxiolytic-like and immunomodulatory activity, while Semax is an ACTH(4-10) analog studied in cognitive research models.
Is Selank for human use?
No. PEPMAKE sells Selank as a lyophilized powder for in-vitro laboratory research only. It is not for human or animal consumption.
What purity should research-grade Selank have?
At least 99% purity measured by HPLC, with identity confirmed by mass spectrometry and a batch-specific Certificate of Analysis (COA).